stdei glp 1 oral solution glp-1 weight loss GLP-1 Oral Solution with Natural Extracts: Peptide Serum π SCAM ALERT π We've
Description
The Basics at a Glance Generic name: Retatrutide (development code: LY3437943) Manufacturer: Eli Lilly and Company Drug class: Triple agonist (GLP-1/GIP/glucagon receptor agonist) Administration: Once-weekly subcutaneous injection Dosing range: 2mg to 12mg weekly (gradual titration over 12+ weeks) Half-life: Approximately 6 days (reaches steady state in 45 weeks) FDA status: Phase 3 clinical trials (TRIUMPH program) Expected approval: 20272028 How Retatrutide Differs from Other GLP-1 Medications To understand retatrutide, it helps to see where it fits in the evolution of GLP-1 class medications
Younger adults were the most open to switching Adults aged 25-34 were the most likely to say they would switch, with 87.38% saying they would likely move to a tablet
Medical Students for Size Inclusivity have created an excelled GLP-1 informed consent guide here
Things You Might Be Wondering What are GLP-1 & GIP Medications
For patients with inadequate response, tirzepatide (a GLP-1/GIP receptor agonist) offers dual-pathway activation and may produce superior weight loss
KDOQIUS Commentary on the KDIGO2024 Clinical Practice Guideline for the Evaluation Management of CKD
